Drug-eluting stents are not indicated for patients with acute coronary syndrome: Should drug-eluting stents be indicated for patients with acute coronary syndrome? (Con)

Circulation Journal

Volumn 74, Issue 10, 2010, Pages 2232-2238

  Inoue, Katsumi ^a  

^a KOKURA MEMORIAL HOSPITAL   (Japan)

Author keywords

Acute coronary syndrome; Drug eluting stent; Pathology; Stent thrombosis

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; ATHEROTHROMBOSIS; BARE METAL STENT; CORONARY STENT; DRUG ELUTING STENT; EPITHELIZATION; HEARING IMPAIRMENT; HEART MUSCLE NECROSIS; HISTOPATHOLOGY; HUMAN; IN-STENT RESTENOSIS; INFLAMMATION; INTRAVASCULAR ULTRASOUND; PATIENT SAFETY; SMOOTH MUSCLE FIBER; STENT THROMBOSIS; THROMBOSIS; TREATMENT INDICATION;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; THROMBOSIS; TREATMENT OUTCOME;

EID: 77958031979     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0722     Document Type: Article

References (48)

1. Morice MC, Serruys PW, Soua JE, Fajadet J, Hayashi EB, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
3. Ko DT, Chiu M, Guo H, Austin PC, Goeree R, Cohen E, et al. Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications. J Am Coll Cardiol 2009; 53: 1773-1782.
4. Harlai KJ, Orshaw P, Boura J, Sporn D. Comparison of long-term outcomes of bare metal or drug-eluting stent implantation in standard versus off-label coronary narrowings. Am J Cardiol 2009; 103: 1537-1545.
5. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrié D, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093-1104.
6. Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, et al. Randomized trial of sirolimus-eluting stent versus baremetal stent in acute myocardial infarction (SESAMI). J Am Coll Cardiol 2007; 49: 1924-1930.
7. Daemen J, Wenawester P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
8. Windecker S, Meier B. Late coronary stent thrombosis. Circulation 2007; 116: 1952-1965.
9. Lemos PA, Saisa F, Hofma SH, Daemen J, Ong ATL, Arampatzis CA, et al. Shot-and long-term clinical benefit of silorimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004; 43: 704-708.
10. Slottow TLP, Steinberg DH, Roy P, Javaid A, Buch AN, Okabe T, et al. Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction. Cardiovasc Revasc Med 2008; 9: 24-28.
11. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol 1997; 17: 1859-1867.
12. Farb A, Burke, Kolodgie FD, Virmani R. Pathological mechanisms of fetal late coronary stent thrombosis in humans. Circulation 2003; 108: 1701-1706.
13. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
14. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, et al. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510.
15. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: An autopsy study. Circulation 2008; 118: 1138-1145.
16. Kubo T, Imanishi T, Kitabata H, Kuroi A, Ueno S, Yamano T, et al. Comparison of vascular responses after sirolimus-eluting stent implantation between patients with unstable and stable angina pectoris: A serial optical coherent tomography study. J Am Coll Cardiol Img 2008; 1: 475-484.
17. Gonzalo N, Barlis P, Serruys PW, Garcia-Garcia HM, Onuma Y, Lighart J, et al. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina: Insights from optical coherence tomography. J Am Coll Cardiol Interv 2009; 2: 445-452.
18. Sehgal SN. Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35(Suppl 3A): 7S-14S.
19. Levin AD, Vulkmirovic N, Hwang CW, Edelman ER. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci USA 2004; 101: 9463-9467.
20. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, et al. Drug-eluting stent and coronary thrombosis: Biological mechanisms and clinical implications. Circulation 2007; 115: 1051-1058.
21. Hwang CW, Levin AD, Jonas M, Li PH, Edelman ER. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation 2005; 111: 1619-1626.
22. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435-2441.
23. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007; 115: 2426-2434.
24. Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction. J Am Coll Cardiol 2007; 50: 573-583.
25. Waller BF. "Crackers, breakers, stretchers, drillers, scrapers, shavers, burners, welders and melters": The future treatment of atherosclerotic coronary artery disease? A clinical-morphologic assessment. J Am Coll Cardiol 1989; 13: 969-987.
26. Meier B, Ramamurthy S. Plaque sealing by coronary angioplasty. Catheter Cardiovasc Diag 1995; 36: 295-297.
27. Inoue K, Abe K, Ando K, Shirai S, Nishiyama K, Nakanishi M, et al. Pathological analyses of long-term intracoronary Palmaz-Schatz stenting: Is its efficacy permanent? Cardiovasc Pathol 2004; 13: 109-115.
28. Libby P, Ridker PM, Hansson G. Inflammation in atherosclerosis. J Am Coll Cardiol 2009; 54: 2129-2138.
29. Higo T, Ueda Y, Oyabu J, Okada K, Nishio M, Hirata A, et al. Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: An angioscopic study. J Am Coll Cardiol Imag 2009; 2: 2616-2624.
30. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1: Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977; 56: 786-794.
31. Lambert L, Brown K, Segal E, Brophy J, Rodes-Cabau J, Bogaty P. Association between timeliness of reperfusion therapy and clinical outcomes in ST-elevation myocardial infarction. JAMA 2010; 303: 2148-2155.
32. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stnkovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-2130.
33. King SB III, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, et al. 2007 Focused Update of the ACC/AHA/ SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/ SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008; 117: 261-295.
34. Steg PG, Fox KAA, Eagle KA, Furman M, Van de Werf E, Montalescot G, et al. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the global registry of acute coronary events. Eur Heart J 2009; 30: 321-329.
35. Toyoda K, Yasaka M, Iwada K, Nagata K, Koretsune Y, Sakamoto T, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: A prospective, multicenter, observational study. Stroke 2008; 39: 1740-1745.
36. Lee SR, Jeong MH, Ahn YK, Chae SC, Hur SH, Kim YJ, et al. Clinical safety of drug-eluting stents in the Korea Acute Myocardial Infarction Registry. Circ J 2008; 72: 392-398.
37. Nomoto K, Watanabe I, Oba T, Nagao K, Kushiro T, Hirayama A. Safety and efficacy of sirolimus-eluting stent in patients with acute coronary syndrome undergoing emergency procedure. Circ J 2008; 72: 1054-1058.
38. Choi CU, Rha SW, Chen KY, Li YJ, Poddar KL, Jin Z, et al. Lack of clinical benefit of improved angiographic results with sirolimuseluting stents compared with paclitaxel and zotarolimus-eluting stents in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Circ J 2009; 73: 2229-2235.
39. Park KW, Kang SH, Chung WY, Lee HY, Park JS, Kang HJ, et al. 'Real world' comparison of drug-eluting stents vs bare metal stents in the treatment of unselected patients with acute ST-segment elevation myocardial infarction. Circ J 2010; 74: 1111-1120.
40. Daemen J, Tanimoto S, García-García HM, Kukreja N, van de Sande M, Sianos G, et al. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol 2007; 99: 1027-1032.
41. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Jüni P, Vaina S, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice: 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008; 52: 1134-1140.
42. Nakagawa Y. What is the effectiveness of drug-eluting stents in the treatment of ST-elevation myocardial infarction?: Should drugeluting stents be indicated for patients with acute coronary syndrome (pro)? Circ J 2010; 74: 2225-2231.
43. Kaltoft A, Kelbæk H, Thuesen L, Lassen JF, Clemmensen P, Kløvgaard L, et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (drug elution and distal protection in acute myocardial infarction) trial. J Am Coll Cardiol 2010 [E-pub ahead of print].
44. Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskina O, Schönig A, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. J Am Coll Cardiol Interv 2009; 2: 291-299.
45. Shiode N, Shirota K, Tsunoda F, Kato Y, Fujiwara M, Mimura M. Late progression after sirolimus-eluting stent implantation for de novo lesions: Comparison with bare metal stent implantation. Circ J 2010; 74: 1104-1110.
46. Virmani R, Liistro F, Stankovic G, Mario CD, Montorfano M, Farb A, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002; 106: 2649-2651.
47. Goto K, Shiode N, Shirota K, Fukuda Y, Kitamura F, Tominaga K, et al. Pathological finding of sirolimus-eluting stent (SES) restenosis lesion with black hole appearance on intravascular ultrasound. Circ J 2009; 73: 1969-1971.
48. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005; 111: 2257-2273.